Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
Cosmo Pharmaceuticals N.V. (“Cosmo”) and Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (“Hikma”) today announced the signing of a license agreement for Winlevi® (clascoterone) cream 1% in the Middle East and North Africa (MENA) region (Kingdom of Saudi Arabia, Jordan, Egypt, Morocco, Algeria, Tunisia, Sudan, Iraq, Lebanon, United Arab Emirates, Qatar, Kuwait, Oman, Bahrain, Yemen, Libya, and Syria).